Median overall survival of 4 years with upfront CDK4/6 inhibition or in second line ...

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

The goals of breast cancer screening are to detect breast cancers as early as possible to reduce both mortality and the ...

The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

People with advanced lung cancer represent a distinct group whose needs remain understudied, especially compared with people diagnosed with limited-stage disease. Fortunately, novel treatments such as ...

Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

Globally, breast cancer is the leading cancer among women. Yet, determining who will develop breast cancer is still a major challenge for the medical community. A new tool, developed by UC San ...

But despite this good news, the overall number of new prostate cancer cases and deaths is on the rise in the U.S.: 2014: 182,806 new prostate cancer cases 2019: 224,733 new prostate cancer cases ...

Thyroid cancer is the most common endocrine malignancy with almost one million people living with thyroid cancer in the United States. Although early-stage well-differentiated thyroid cancers account ...